{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:24:24Z","timestamp":1776486264408,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.cllc.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T10:43:28Z","timestamp":1726137808000},"page":"712-722.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Alexander S.","family":"Watson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harris B.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"VanderWalde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Sledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Spetzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L.","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cllc.2024.09.001_bib0001","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage iv non\u2013small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.cllc.2024.09.001_bib0002","first-page":"00159","article-title":"Oncogene overlap analysis of circulating cell-free tumor DNA to explore the appropriate criteria for defining MET copy number-driven lung cancer","volume":"S1525-7304","author":"Tsui","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"10299","key":"10.1016\/j.cllc.2024.09.001_bib0003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2024.09.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cllc.2021.08.012","article-title":"The effects of HER2 alterations in EGFR mutant non-small cell lung cancer","volume":"23","author":"Nagasaka","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2024.09.001_bib0007","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.lungcan.2009.11.020","article-title":"KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies","volume":"69","author":"Mao","year":"2010","journal-title":"Lung Cancer Amst Neth"},{"issue":"8","key":"10.1016\/j.cllc.2024.09.001_bib0008","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number\u2013driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2024.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2024.09.001_bib0010","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cllc.2024.09.001_bib0011","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","article-title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","volume":"31","author":"Schuler","year":"2020","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2024.09.001_bib0012","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1200\/JCO.2021.39.15_suppl.9021","article-title":"Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp)","volume":"39","author":"Le","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2024.09.001_bib0013","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1016\/j.cllc.2021.05.002","article-title":"Co-occurring MET Amplification predicts inferior clinical response to first-line erlotinib in advanced stage EGFR-mutated NSCLC patients","volume":"22","author":"Clement","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"5827","key":"10.1016\/j.cllc.2024.09.001_bib0014","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cllc.2024.09.001_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.02.007","article-title":"Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib","volume":"118","author":"Wang","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2024.09.001_bib0018","article-title":"HER2-altered non-small cell lung cancer: biology, clinicopathologic features, and emerging therapies","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"issue":"19","key":"10.1016\/j.cllc.2024.09.001_bib0019","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/cancers13195023","article-title":"MET amplification in non-small cell lung cancer (NSCLC)\u2014a consecutive evaluation using next-generation sequencing (NGS) in a real-world setting","volume":"13","author":"Schubart","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cllc.2024.09.001_bib0020","doi-asserted-by":"crossref","first-page":"v800","DOI":"10.1093\/annonc\/mdz269.009","article-title":"Identification of MET gene amplifications using next-generation sequencing in nonsmall cell lung cancer patients","volume":"30","author":"Clav\u00e9","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0021","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"issue":"3","key":"10.1016\/j.cllc.2024.09.001_bib0022","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.09.001_bib0023","doi-asserted-by":"crossref","first-page":"826","DOI":"10.21037\/tlcr-20-927","article-title":"Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients","volume":"10","author":"Fung","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0024","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12885-023-10674-z","article-title":"Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-021-01138-7","article-title":"Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer","volume":"14","author":"Drusbosky","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.cllc.2024.09.001_bib0026","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2407-11-93","article-title":"Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer","volume":"11","author":"Newnham","year":"2011","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.cllc.2024.09.001_bib0027","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non\u2013small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.001_bib0028","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/1471-2407-10-376","article-title":"Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas","volume":"10","author":"Liang","year":"2010","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2024.09.001_bib0029","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non\u2013small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.cllc.2024.09.001_bib0030","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.1200\/JCO.2023.41.16_suppl.9118","article-title":"Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer","volume":"41","author":"Ricciuti","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2024.09.001_bib0031","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/PO.19.00333","article-title":"Targeting HER2 alterations in non\u2013small-cell lung cancer: a comprehensive review","author":"Zhao","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"23","key":"10.1016\/j.cllc.2024.09.001_bib0032","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1158\/1078-0432.CCR-18-0876","article-title":"Amplification of wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non\u2013small cell lung cancer","volume":"24","author":"Bahcall","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cllc.2024.09.001_bib0033","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00428-019-02555-3","article-title":"Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics","volume":"474","author":"Eijkelenboom","year":"2019","journal-title":"Virchows Arch"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T23:47:46Z","timestamp":1732319266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424001967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1525730424001967"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.09.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}